Improved visualization of carcinoid liver metastases by indium-111 pentetreotide scintigraphy following treatment with cold somatostatin analogue.
Five patients with hepatic metastases of midgut carcinoid underwent somatostatin receptor scintigraphy with indium-111 pentetreotide before and during treatment with octreotide. Octreotide treatment changed the biodistribution of 111In-pentetreotide significantly. Whereas the radioactivity in liver, spleen and kidney decreased, hepatic metastases showed increased contrast. In one patient, liver metastases could only be detected during octreotide treatment. These data suggest that the diagnostic reliability of somatostatin receptor scintigraphy in carcinoid liver metastases is not necessarily compromised by octreotide therapy. Because of different biodistributions, the detection of liver metastases may even be improved during octreotide therapy.
Dörr
U
U
Department of Nuclear Medicine, Katharinenhospital, Stuttgart, Germany.
Räth
U
U
Sautter-Bihl
M L
ML
Guzman
G
G
Bach
D
D
Adrian
H J
HJ
Bihl
H
H
D002276:Carcinoid Tumor / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000556:secondary*; D006801:Humans; D007205:Indium Radioisotopes; D007414:Intestinal Neoplasms / Q000188:drug therapy / Q000473:pathology*; D008113:Liver Neoplasms / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000556:secondary*; D015282:Octreotide / Q000627:therapeutic use*; D011877:Radionuclide Imaging; D013004:Somatostatin / Q000031:analogs & derivatives*; D014018:Tissue Distribution
D007205:Indium Radioisotopes; D013004:Somatostatin; C081788:pentetreotide; D015282:Octreotide